In vitro and in vivo protection against enterovirus 71 by an antisense phosphorothioate oligonucleotide
暂无分享,去创建一个
Jing Yang | Shengqi Wang | Zhe Zhou | Kang Li | Juan Liu | Mingming Han
[1] Man Tsuey Tse. Regulatory watch: Antisense approval provides boost to the field , 2013, Nature Reviews Drug Discovery.
[2] Kuo-Feng Weng,et al. Viral and host factors that contribute to pathogenicity of enterovirus 71. , 2012, Future microbiology.
[3] H. Kung,et al. The virology and developments toward control of human enterovirus 71 , 2011, Critical reviews in microbiology.
[4] D. A. Stein,et al. Development of Peptide-Conjugated Morpholino Oligomers as Pan-Arenavirus Inhibitors , 2011, Antimicrobial Agents and Chemotherapy.
[5] Daniel Jones. The long march of antisense , 2011, Nature Reviews Drug Discovery.
[6] Yan Jin,et al. A large outbreak of hand, foot, and mouth disease caused by EV71 and CAV16 in Guangdong, China, 2009 , 2011, Archives of Virology.
[7] M. Phoon,et al. The largest outbreak of hand; foot and mouth disease in Singapore in 2008: the role of enterovirus 71 and coxsackievirus A strains. , 2010, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[8] J. Chu,et al. Developments towards antiviral therapies against enterovirus 71 , 2010, Drug Discovery Today.
[9] Huaxi Xu,et al. Epidemiology of hand, foot, and mouth disease and genotype characterization of Enterovirus 71 in Jiangsu, China. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[10] S. Koike,et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71 , 2009, Nature Medicine.
[11] D. A. Stein. Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers. , 2008, Current pharmaceutical design.
[12] Ruiwen Zhang,et al. Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible? , 2008, Drug discovery today.
[13] K. Ruxrungtham,et al. HIV drug resistance transmission threshold survey in Bangkok, Thailand , 2008, Antiviral therapy.
[14] Jing Yang,et al. In vitro and in vivo Protection against the Highly Pathogenic H5N1 Influenza virus by an Antisense Phosphorothioate Oligonucleotide , 2008, Antiviral therapy.
[15] V. Chow,et al. Inhibition of Enterovirus 71 in Virus-infected Mice by RNA Interference. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[16] B. Davidson,et al. Transvascular delivery of small interfering RNA to the central nervous system , 2007, Nature.
[17] Xiuli Wu,et al. A CpG oligodeoxynucleotide inducing anti‐coxsackie B3 virus activity in human peripheral blood mononuclear cells , 2007, FEMS immunology and medical microbiology.
[18] C. Potera. Antisense—down, but not out , 2007, Nature Biotechnology.
[19] V. Chow,et al. Enhanced potency and efficacy of 29-mer shRNAs in inhibition of Enterovirus 71. , 2007, Antiviral research.
[20] C. Poh,et al. Inhibition of enterovirus 71 in virus-infected mice by RNA interference. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] Jing Yang,et al. Selection of antisense oligonucleotides based on multiple predicted target mRNA structures , 2006, BMC Bioinformatics.
[22] V. Chow,et al. RNA interference against enterovirus 71 infection. , 2005, Virology.
[23] D. A. Stein,et al. Inhibition of Flavivirus Infections by Antisense Oligomers Specifically Suppressing Viral Translation and RNA Replication , 2005, Journal of Virology.
[24] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[25] S. Kung,et al. Selective inhibition of enterovirus 71 replication by short hairpin RNAs. , 2004, Biochemical and biophysical research communications.
[26] John J Rossi,et al. Approaches for the sequence-specific knockdown of mRNA , 2003, Nature Biotechnology.
[27] K. McKnight,et al. RNA as a Target for Developing Antivirals , 2003, Antiviral chemistry & chemotherapy.
[28] J. Kopeček,et al. Antisense oligonucleotides delivered to the lysosome escape and actively inhibit the hepatitis B virus. , 2002, Bioconjugate chemistry.
[29] M. Carbone,et al. The Role of Environmental Carcinogens, Viruses, and Genetic , 2002, Cancer biology & therapy.
[30] N. Dias,et al. Antisense oligonucleotides: basic concepts and mechanisms. , 2002, Molecular cancer therapeutics.
[31] P. McMinn,et al. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[32] T. Abe,et al. Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus. , 2000, Biochemical and biophysical research communications.
[33] Shin-Ru Shih,et al. Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease , 1999, The Lancet.
[34] Kow-Tong Chen,et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. , 1999, The New England journal of medicine.
[35] T. Yeh,et al. Neurologic complications in children with enterovirus 71 infection. , 1999, The New England journal of medicine.
[36] Daniel C. Pevear,et al. Activity of Pleconaril against Enteroviruses , 1999, Antimicrobial Agents and Chemotherapy.
[37] K. Chua,et al. Fatal enterovirus 71 encephalomyelitis. , 1998, The Journal of pediatrics.
[38] Advances in CMV management: fomivirsen (Vitravene) approved. , 1998, Project Inform perspective.
[39] M. Pallansch,et al. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. , 1995, Virus research.
[40] T. Hyypiä,et al. Molecular comparison of coxsackie A virus serotypes. , 1995, Virology.
[41] L. Vance,et al. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus , 1995, Journal of virology.
[42] M. Stephenson,et al. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[43] E. H. Lennette,et al. An apparently new enterovirus isolated from patients with disease of the central nervous system. , 1974, The Journal of infectious diseases.